Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Nektar Therapeutics (NKTR)

Q2 2012 Earnings Call

August 09, 2012 17:00 p.m. E.T

Executives

Jennifer Ruddock – Investor Relations

Howard Robin – Chief Executive Officer

John Nicholson – Chief Financial Officer

Robert Medve – Chief Medical Officer

Analysts

Jonathan Aschoff – Brean, Murray

Bob Hazlett – Roth Capital

Rashie Jain – JP Morgan

Biren Amin – Jefferies

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Second Quarter 2012 Financial Results Conference Call. My name is Erin, and I’ll be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session toward the end of today’s conference. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes.

I would now turn the presentation over to your host for today’s call, Ms. Jennifer Ruddock. Please proceed, ma’am.

Jennifer Ruddock

Good afternoon and thank you for joining us. With us today are Howard Robin, our President and CEO, John Nicholson, our Chief Financial Officer, Dr. Robert Medve, our Chief Medical Officer and Dr. Steve Doberstein, our Chief Scientific Officer.

On this call, we expect to make forward looking statements regarding our business including but not limited to clinical development plans, the timing of future clinical results and regulatory filings, the economic potential of our collaboration partnerships including potential milestone payments, the therapeutic and market potential of our drug candidates and those of our partners, our financial guidance for 2012, and certain other statements regarding the future of our business.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our Annual Report on Form 10-K filed in February and our Form 8-k filed today. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise. A webcast of this conference call will be available for replay on the Investor Relations page at Nektar’s website at www.nektar.com.

If you liked this article you might like

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct